Refractory Behçet’s Disease with Multi-organ Involvement - Learning from Failure

Author(s): Christiana Sieiro Santos*, Clara Moriano Morales, Elvira Díez Álvarez, Trinidad Pérez Sandoval

Journal Name: Current Rheumatology Reviews

Volume 17 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Behçet’s disease (BD) is a rare systemic vasculitis of unknown etiology with relapsing and remitting course, characterized by triple-symptom complex of recurrent attacks of oral aphthous ulcers, genital ulcers and ocular lesions and other clinical features that include dermatological, cardiovascular, gastrointestinal, and neurological manifestations. The main goal of management is to prevent relapses and suppress inflammation rapidly for major organ involvement that may cause damage and even be fatal.

Case Presentation: We hereby describe a case of a patient with Behçet’s disease followed in our rheumatology consultation over the course of 15 years with multi-organ involvement resistant to several treatments and showed partial results with IL-1 inhibitors, particularly anakinra and canakinumab, while also discussing the current treatments of refractory BD and how early implementation of treatments could make a difference.

Keywords: Behçet, refractory, vasculitis, intestinal, ulcers, case report.

[1]
Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med 1999; 341(17): 1284-91.
[http://dx.doi.org/10.1056/NEJM199910213411707] [PMID: 10528040]
[2]
Cohen L. Etiology, pathogenesis and classification of aphthous stomatitis and Behçet’s syndrome. J Oral Pathol 1978; 7(6): 347-52.
[http://dx.doi.org/10.1111/j.1600-0714.1978.tb01601.x] [PMID: 105093]
[3]
Leonardo NM, McNeil J. Behcet’s disease: is there geographical variation? a review far from the silk road. Int J Rheumatol 2015; 2015: 945262.
[http://dx.doi.org/10.1155/2015/945262] [PMID: 26798344]
[4]
International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335(8697): 1078-80.
[PMID: 1970380]
[5]
International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28(3): 338-47.
[http://dx.doi.org/10.1111/jdv.12107] [PMID: 23441863]
[6]
Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol 2017; 13(1): 57-65.
[http://dx.doi.org/10.1080/1744666X.2016.1205486] [PMID: 27351485]
[7]
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 2018; 77(6): 808-18.
[http://dx.doi.org/10.1136/annrheumdis-2018-213225] [PMID: 29625968]
[8]
Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal behçet disease. Gastroenterol Hepatol (N Y) 2012; 8(2): 103-12.
[PMID: 22485077]
[9]
Cho SB, Cho S, Bang D. New insights in the clinical understanding of Behçet’s disease. Yonsei Med J 2012; 53(1): 35-42.
[http://dx.doi.org/10.3349/ymj.2012.53.1.35] [PMID: 22187230]
[10]
Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T. Intestinal involvement in Behçet’s disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 1981; 24(2): 103-6.
[http://dx.doi.org/10.1007/BF02604297] [PMID: 7215071]
[11]
Ideguchi H, Suda A, Takeno M, et al. Gastrointestinal manifestations of Behçet’s disease in Japan: a study of 43 patients. Rheumatol Int 2014; 34(6): 851-6.
[http://dx.doi.org/10.1007/s00296-013-2838-5] [PMID: 23934478]
[12]
Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations. J Neurol 2014; 261(9): 1662-76.
[http://dx.doi.org/10.1007/s00415-013-7209-3] [PMID: 24366648]
[13]
Koçer N, Islak C, Siva A, et al. CNS involvement in neuro-Behçet syndrome: an MR study. AJNR Am J Neuroradiol 1999; 20(6): 1015-24.
[PMID: 10445437]
[14]
Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol 2017; 69(12): 2380-5.
[http://dx.doi.org/10.1002/art.40235] [PMID: 28834393]
[15]
Ma D, Zhang CJ, Wang RP, Wang L, Yang H. Etanercept in the treatment of intestinal Behcet’s disease. Cell Biochem Biophys 2014; 69(3): 735-9.
[http://dx.doi.org/10.1007/s12013-014-9860-4] [PMID: 24622940]
[16]
Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: A multicenter retrospective observational study. Mod Rheumatol 2017; 27(6): 1031-5.
[http://dx.doi.org/10.1080/14397595.2017.1285857] [PMID: 28712320]
[17]
Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 1990; 322(5): 281-5.
[http://dx.doi.org/10.1056/NEJM199002013220501] [PMID: 2404204]
[18]
Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19(5): 542-9.
[http://dx.doi.org/10.3109/s10165-009-0200-2] [PMID: 19597921]
[19]
Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet’s syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
[20]
De Luca G, Cariddi A, Campochiaro C, et al. Efficacy and safety of apremilast for Behçet’s syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford) 2020; 59(1): 171-5.
[http://dx.doi.org/10.1093/rheumatology/kez267] [PMID: 31280296]
[21]
Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 2002; 29(5): 267-79.
[http://dx.doi.org/10.1111/j.1346-8138.2002.tb00263.x] [PMID: 12081158]
[22]
Grayson PC, Yazici Y, Merideth M, et al. Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open-label study. Arthritis Res Ther 2017; 19(1): 69.
[http://dx.doi.org/10.1186/s13075-017-1222-3] [PMID: 28335798]
[23]
Zou J, Guan JL. Interleukin-1-related genes polymorphisms in Turkish patients with Behçet disease: a meta-analysis. Mod Rheumatol 2014; 24(2): 321-6.
[http://dx.doi.org/10.3109/14397595.2013.844304] [PMID: 24252048]
[24]
Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol 2015; 34(7): 1293-301.
[http://dx.doi.org/10.1007/s10067-013-2443-8] [PMID: 24305945]
[25]
Vitale A, Rigante D, Caso F, et al. Inhibition of interleu- 17 Park YE and Cheon JH. Updated therapy for intestinal Behçet’s disease by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet’s disease: a case series. Dermatology 2014; 228: 211-4.
[http://dx.doi.org/10.1159/000358125] [PMID: 24642905]
[26]
Mirouse A, Barete S, Monfort JB, et al. Ustekinumab for Behçet’s disease. J Autoimmun 2017; 82: 41-6.
[http://dx.doi.org/10.1016/j.jaut.2017.05.002] [PMID: 28483439]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 3
Year: 2021
Published on: 28 December, 2020
Page: [360 - 364]
Pages: 5
DOI: 10.2174/1573403X16999201228205028
Price: $65

Article Metrics

PDF: 510
HTML: 7